what are the Recommendations for HF With Mildly Reduced Ejection Fraction
Referenced studies that support the recommendations are summa-
rized in the Online Data Supplements.?
Among patients with current or previous symp- tomatic HFmrEF (LVEF, 41%?49%), use of evidence-based beta blockers for HFrEF, ARNi, ACEi, or ARB, and MRAs may be considered to reduce the risk of HF hospitalization and cardiovascular mortality, particularly among patients with LVEF on the lower end of this spectrum.